Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026

Alterity Therapeutics highlights its Multiple System Atrophy program as it joins a fireside chat at the Cantor Global Healthcare Conference 2026.

Rhea-AI Summary

Alterity Therapeutics (ATHE) will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET.

The live and archived webcast will be available via the Investors > Events and Presentations section of the company’s website. Alterity is a clinical stage biotechnology company developing disease modifying therapies for neurodegenerative diseases, with a focus on Multiple System Atrophy (MSA) and related Parkinsonian disorders. The company is preparing to initiate a Phase 3 pivotal trial in MSA with its lead asset ATH434, which has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial and positive data in an open label Phase 2 trial in participants with advanced MSA.

Market Context

ATHE recorded a 4.35% 24-hour move after its August 6 conference-participation announcement. That pr...

Analysis

ATHE recorded a 4.35% 24-hour move after its August 6 conference-participation announcement. That precedent helps frame this notice, which contains no new clinical results; the key risk is limited substantive disclosure.

Key Figures

Conference Date: September 11, 2026 Chat Time: 10:20 a.m. ET Trial Phase: Phase 3 +1 more

4 metrics

Conference Date September 11, 2026 Cantor Global Healthcare Conference 2026

Chat Time 10:20 a.m. ET Fireside Chat in the United States

Trial Phase Phase 3 Planned pivotal trial in MSA

Prior Trial Phase Phase 2 ATH434 randomized clinical trial in MSA

Historical Context

5 past events · Latest: Aug 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 12	Patent grant	Positive	+4.5%	New U.S. patent extended ATH434 composition-of-matter protection to at least 2045.
Aug 06	Conference presentation	Neutral	+4.3%	CEO scheduled to present at the Canaccord Genuity Growth Conference.
Jul 30	Cash flow update	Positive	+1.2%	FDA pathway, Phase 3 planning, cash balance, and quarterly operating outflows were reported.
Jul 21	Conference participation	Neutral	+5.1%	CEO scheduled investor meetings at the virtual BTIG Biotechnology Conference.
Jul 07	FDA pathway	Positive	-6.8%	FDA meeting minutes confirmed key elements of the registrational Phase 3 program.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

ATHE generally recorded positive reactions to corporate and conference announcements, while its FDA pathway update produced a negative reaction.

Key Terms

phase 3, double-blind, placebo-controlled, open label

4 terms

phase 3 medical

"Alterity is preparing to initiate a Phase 3 pivotal trial in MSA"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

double-blind medical

"demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled"

A double-blind process means that neither the people conducting an activity nor the people involved know certain key details, such as who is receiving a treatment or a placebo. This approach helps prevent bias from influencing the results, making the outcome more trustworthy. For investors, it ensures that decisions or judgments are based on unbiased information rather than preconceived opinions or expectations.

placebo-controlled medical

"randomized, double-blind, placebo-controlled Phase 2 clinical trial"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

open label medical

"positive data in its open label Phase 2 clinical trial"

Open label is a clinical trial design in which both the participants and the researchers know which treatment or intervention is being given. For investors, this matters because knowledge of the treatment can influence reported effects and side effects—like how seeing a product label can change a shopper’s opinion—so open-label results are useful for safety and real-world experience but are generally viewed as less rigorous evidence of effectiveness than blinded studies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States.

A link to the live and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations.

About Alterity Therapeutics Limited

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

Authorisation & Additional information
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

Contacts:

Investors
Elyse Shapiro
ir@alteritytx.com

Remy Bernarda
Investor Relations Advisory Solutions
ir@alteritytx.com
+1 (415) 203-6386

Media
Melissa Tempra
NWR Communications
melissa@nwrcommunications.com.au

Casey McDonald
Tiberend Strategic Advisors, Inc.
cmcdonald@tiberend.com
+1 (646) 577-8520

FAQ

When will Alterity Therapeutics (ATHE) present at the Cantor Global Healthcare Conference 2026?

Alterity Therapeutics’ CEO, David Stamler, M.D., will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States.

How can investors access the Alterity Therapeutics (ATHE) fireside chat webcast from the Cantor conference?

The live and archived webcast of Alterity Therapeutics’ Fireside Chat can be accessed through the company’s website in the Investors section under Events and Presentations, allowing investors to watch both in real time and on demand after the event.

What is the main therapeutic focus of Alterity Therapeutics (ATHE)?

Alterity Therapeutics is focused on developing disease modifying therapies for Multiple System Atrophy (MSA) and related Parkinsonian disorders. The company describes itself as dedicated to creating an alternate future for people living with neurodegenerative diseases through its clinical programs and discovery platform.

What is ATH434 in Alterity Therapeutics’ (ATHE) pipeline and what trial results have been reported?

ATH434 is Alterity Therapeutics’ lead asset for treating MSA. It has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in participants with MSA, and the company has also reported positive data from an open label Phase 2 trial in participants with advanced MSA.

What stage is Alterity Therapeutics’ (ATHE) Multiple System Atrophy program in?

Alterity Therapeutics is a clinical stage company and is preparing to initiate a Phase 3 pivotal trial in Multiple System Atrophy. This planned trial builds on Phase 2 results with its lead candidate ATH434 and targets this rare, rapidly progressive neurodegenerative disease.